OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)

Dulaglutide (DU) approved at doses of 0.75 and 1.5 mg once-weekly is an effective glucose lowering agent for treatment of type 2 diabetes (T2D). We hypothesized that higher investigational DU doses may provide further improvements in glucose control and body weight (BW) with an acceptable safety pro...

詳細記述

保存先:
書誌詳細
出版年:J Endocr Soc
主要な著者: Frias, Juan Pablo, Ruiz, Luis Nevárez, Li, Ying Grace, Yu, Zhuoxin, Milicevic, Zvonko, Woodward, Brad, Cox, David A
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2020
主題:
Diabetes Mellitus and Glucose Metabolism
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209020/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.2057
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料